On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

ISLAMABAD: The Competition Commission of Pakistan (CCP) Friday approved the acquisition of trademarks for the pharmaceutical ...

Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine ...

French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to ...

US planemaker Boeing is heading into a busy week, with investors watching developments closely around its costly labour strike, as well as its latest quarterly results. More than 33,000 unionised ...

The Competition Commission of Pakistan (CCP) on Friday approved the acquisition of trademarks for the pharmaceutical product ...